About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Leukemia Research
›
Top Articles
Leukemia Research
Hematology
,
Oncology
2.7
(top 8%)
Impact Factor
3
(top 8%)
extended IF
99
(top 3%)
H-Index
3.9K
authors
8K
papers
133.9K
citations
5.5K
citing journals
50.4K
citing authors
Most Cited Articles of Leukemia Research
Title
Year
Citations
Diagnostic criteria and classification of mastocytosis: a consensus proposal
2001
871
Establishment of an immature mast cell line from a patient with mast cell leukemia
1988
645
Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI
2003
409
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
2007
393
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
1984
315
1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells
1983
275
Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy
2001
266
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
2009
251
Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H
1998
238
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
2007
237
A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors
1985
230
Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients
2000
225
Cyclin: a nuclear protein whose level correlates directly with the proliferative state of normal as well as transformed cells
1984
215
Human CD38: a (r)evolutionary story of enzymes and receptors
2001
212
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review
2010
208
HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells
2006
204
Hematopoietic-specific microRNA expression in human cells
2006
203
MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation
1999
200
Properties and usefulness of the original K-562 human myelogenous leukemia cell line
1979
199
The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells
1994
197
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings
2001
185
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria
2003
184
Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis
2001
184
Phenotypic heterogeneity and cellular origins of T cell malignancies
1981
177
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
2009
173
previous
2010
2011
2012
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.